Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients

December 17, 2018
Janssen Pharmaceutical said on December 14 that it has applied for an additional indication for including previously untreated multiple myeloma (MM) for its anti-CD38 monoclonal antibody Darzalex (daratumumab) in Japan. The efficacy and safety of Darzalex used in combination with...read more